DALLAS, March 8, 2010 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Keryx Biopharmaceuticals Inc. (Nasdaq:KERX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.investorsoup.com/lp/KERX
Get our alerts BEFORE the rest of the market on Twitter: http://www.twitter.com/investorsoup
Keryx Biopharmaceuticals Inc. (KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. The Company is developing Zerenex (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end stage renal disease (ESRD). Keryx is developing KRX-0401 (perifosine), an oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 is in Phase 2 clinical development for multiple tumor types.
In the report, the analyst notes:
"At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008. On September 30, 2009, the Company completed a $20.0 million registered direct offering of common stock and warrants, which provided proceeds to the Company of approximately $18.4 million, net of offering costs of approximately $1.6 million, which were paid subsequent to September 30, 2009.
"Zerenex (ferric citrate) is an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a U.S. Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and the Phase 3 clinical program of Zerenex is pending commencement under an SPA agreement with the FDA. Zerenex is also in Phase 2 development in Japan by the Company's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd."
Read the entire report: http://www.investorsoup.com/lp/KERX
See what investors say about KERX: penny stock forum
InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit www.InvestorSoup.com/">http://www.InvestorSoup.com
InvestorSoup.com Disclosure
InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither InvestorSoup nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, InvestorSoup.com, for complete risks and disclosures.